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Abstract
Background and aim: Limited data suggests that pseudomembranes are uncommon in patients
with inflammatory bowel disease (IBD) and C. difficile associated disease (CDAD), but the reason
for this is unknown.
We aimed to evaluate the rate of pseudomembranes in this population, identify predictive
factors for pseudomembranes' presence and assess its clinical impact.
Methods: This was a sub-study of a retrospective European Crohn's & Colitis Organization (ECCO)
multi-center study on the outcome of hospitalized IBD patients with C. difficile. The present study
included only patients who underwent lower endoscopy during hospitalization, and compared
demographic and clinical parameters in the group of patients with discernable pseudomembranes
versus those without.
Results: Out of 155 patients in the original cohort, 93 patients underwent lower endoscopy and
constituted the study population. Endoscopic pseudomembranes were found in 12 (13%) of these
patients. Patients with pseudomembranes presented more commonly with fever (p=0.02)
compared to patients without pseudomembranes. No difference between the two groups was
found with respect to the use of immunosuppressant drugs, background demographics or disease
characteristics. Neither was there a difference between the group with or without pseudomem-
branes in the frequency of severe adverse clinical outcome or in the duration of hospitalization. On
multi-variate analysis the presence of fever remained independently associated with the finding of
pseudomembranes (OR 6, 95% CI 1.2–32, p=0.03).
Conclusions: This study documents that hospitalized IBD patients with CDAD have low rate of
endoscopic pseudomembranes, which is not accounted for by the use of immunosuppressant
drugs. IBD patients with CDAD and discernable pseudomembranes more commonly present with
fever, but their clinical outcome is similar to patients without pseudomembranes.
© 2009 Published by Elsevier B.V. on behalf of European Crohn's and Colitis Organisation.rin S, et al, Prevalence and
stridium difficile infection, J1. Introduction and background
The incidence and severity of Clostridium difficile associated
disease (CDAD) among patients with inflammatory bowel
disease (IBD) is greater than its rate in the non-IBD
population,1,2 and the incidence is increasing in recent
years.3,4 Clinical guidelines have therefore advocated the
early diagnosis and treatment of CDAD in flaring IBD patients.5
CDAD in the IBD population may manifest differently than
in other population, making its symptoms indistinguishable
from an exacerbation of IBD. For instance, bloody diarrhea is
commonly present in cases of CDAD in IBD whereas loose
watery diarrhea is the hallmark of CDAD in other popula-
tions.6–8 Moreover, recent evidence suggest that up to 8% of
IBD patients in remission harbor colonizing toxicogenic
C. difficile, 9 thereby casting some doubt on the diagnostic
interpretation of a positive toxin assay in this unique
population. In addition to these diagnostic caveats, anec-
dotal reports suggest that pseudomembranes may be less
common among IBD patients with CDAD compared to other
populations. However, this has not been well documented.
Moreover, there are no studies pertaining to the clinical
significance of the absence or presence of pseudomembranes
in IBD patients.
Thus, the present study aimed to investigate the
frequency of pseudomembranes among patients with IBD
and CDAD. A secondary aim was to explore clinical predictors
for the occurrence of pseudomembranes and to elucidate
their clinical impact.cli
Cro2. Methods
2.1. Study design and population
This was a sub-study of a European Crohn's & Colitis
Organization (ECCO) multi-center retrospective study previ-
ously reported elsewhere.6 The source study encompassed
all patients hospitalized with a co-diagnosis of IBD and
concomitant CDAD from 1st January 2000 to 1st March 2008
in the participating centers. Details on the methods of cases
identification and definition of treatment can be found in the
original report.6 In the present study, a sub-analysis was
performed only for patients who underwent lower endoscopy
during their hospitalization and in whom the presence or
absence of endoscopic pseudomembranes was recorded. The
presence of pseudomembranes was defined by the original
report written by the performing endoscopist at each center.
Patients were divided into a group with pseudomembranes
and a group without, and the two groups were compared for
the use of immunosuppressant drugs, demographic and
clinical parameters, as well as the clinical outcome of
hospitalization. The main clinical outcome investigated was
a composite outcome comprised of the following para-
meters: mortality or colectomy within 3 months of admission
with CDAD-IBD (in-hospital or after discharge), colon
perforation or megacolon during hospitalization, shock
(defined by the need for intravenous vasopressive support),
or the need for mechanical ventilation. Additional clinical
outcomes compared between the groups with and withoutnical impact of endoscopic pseudomembranes in patients with
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need to substitute antibiotics due to CDAD persistence and
CDAD relapse—defined as re-hospitalization within 3 months
with an admission diagnosis of CDI.
The study was approved centrally by the ethics commit-
tee of the Sheba Medical Center, and was also approved or
exempted locally by the respective ethics committee at each
of the participating centers.
2.2. Statistical analysis
Continuous variables were analyzed by two-tailed Student
t-test or Mann–Whitney U-test, as appropriate, and categor-
ical variables were analyzed by Fisher Exact test. Correlations
were tested by Spearman's rank correlation test. Variables
differing between groups with a significance level of Pb0.15
were then entered intomulti-variate analysismodel consisting
of a multiple backward logistic regression to identify factors
independently affecting dichotomous clinical outcomes. All
statistics were performed using MedCalc software (Maria-
kerke, Belgium). Pb0.05 was considered significant.
3. Results
Out of the 155 patients of the original study, who were
hospitalized with IBD and CDAD in the 20 participatingTable 1 Background demographic and clinical characteristics.
All patients
(n=93)
Patients witho
(n=81)
Age (years, median±SD) 42±18 43±18
Females 54 (58%) 49 (60%)
UC 65 (70%) 57 (70%)
Mean duration of disease (years) 6.3±8 6.4±8
Hospitalization in prior 3 months 24 (26%) 21 (27%)
Antibiotics in prior 3 months 41 (44%) 36 (44%)
PPI use in prior 3 months 13 (16%) 11 (15%)
Any co-morbidities 32 (34%) 29 (36%)
Admission after 2003 69 (74%) 61(76%)
Any immunomodulators on admission 32 (34%) 28 (35%)
Corticosteroids on admission 28 (30%) 25 (31%)
Underwent colonoscopy 37 (40%) 30 (37%)
Abdominal pain 59 (63%) 49 (60%)
Severe diarrhea (N6 BM/day) a 63 (73%) 54 (73%)
Fever at onset a 37 (42%) 26 (35%)
Abdominal tenderness a 50 (55%) 42 (53%)
Blood in stool 67 (72%) 59 (73%)
Elevated Creatinine a 20 (23%) 19 (24%)
Leukocytosis N10 k/ml 51 (55%) 42 (51%)
Elevated CRP a 76 (92%) 65 (90%)
Hbb10.5 g/dl 26 (29%) 21 (26%)
Hypoalbuminemiab3.5 mg/dl a 49 (62%) 41 (60 a)
Mean duration of hospitalization (days) 17±14 17±15
Relapse 13 (14%) 10 (12%)
C. difficile treatment failure 11 (12%) 8 (10%)
Adverse outcome 9 (10%) 9 (11%)
The p values represent the comparison between the group with and w
a Percentages are calculated out of the patients with available data.
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endoscopy. These patients comprised the study population.
Endoscopic pseudomembranes were detected in 12 (13%) of
these patients, coming from 7 centers (4 patients with
pseudomembranes were found in a single center at Belgrade
out of the 8 patients endoscoped at that site). In 77 (83%) of
the total 93 patients, biopsies were obtained and available.
Histological pseudomembranes were found in 3 specimens. In
one of these 3 patients, microscopic pseudomembranes were
reported in the absence of macroscopically discernable
pseudomembranes at endoscopy. In 90 out of 93 patients,
the diagnosis was made by positive toxin enzyme immuno-
assay. One patient was diagnosed by positive C. difficile
culture (culture was positive in additional 8 patients who had
also positive toxin assay). Two patients were diagnosed
solely by histological documentation of pseudomembranes.
The clinical characteristics of the study cohort, stratified
according to the presence or absence of endoscopic
pseudomembranes are shown in Table 1. A similar rate of
immuno-modulator drugs' use was found in the two groups
(Table 1), and the two groups did not differ with respect to
the diagnostic procedure they underwent (i.e. colonoscopy
or sigmoidoscopy). The presence of fever at the onset of
disease was more common among patients with pseudomem-
branes compared to patients without (9/12 vs. 26/81,
P=0.02, Fisher Exact test). Elevated leukocyte count was
also more frequent in the group with pseudomembranes, butut pseudomembranes Patients with pseudomembranes
(n=12)
P value
39±15 0.5
5 (42%) 0.3
8 (66 %) 0.7
5.9±6 0.6
3 (25%) 0.9
5 (42%) 0.7
2 (17%) 0.9
3 (25%) 0.5
8 (75%) 0.5
4 (33%) 0.9
3 (25%) 0.9
7 (58%) 0.2
10 (83%) 0.2
9 (75%) 0.9
9 (75%) 0.02
8 (66%) 0.5
8 (75%) 0.5
1 (10%) 0.4
9 (82%) 0.1
11 (100%) 0.6
5 (42%) 0.3
8 (80%) 0.3
15±10 0.8
3 (25%) 0.3
3 (25%) 0.15
0 (0%) 0.6
ithout pseudomembranes
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Table 2 Multi-variate analysis by backward logistic regression
showing theodds ratio for occurrenceof pseudomembranes for
parameters found on uni-variate analysis to correlate with this
finding with a significance level of P≤0.15.
Parameter Odds ratio Confidence
interval
P value
Fever at onset 6.2 1.2–32 0.03
Leukocytosis N10 k/ml 3 0.6–15 0.2
C. difficile treatment
failure
2.7 0.5–14 0.24
4 S. Ben-Horin et al.
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Importantly, therewas no difference in the clinical outcomeof
the two groups with respect to death or colectomy within
3 months of hospitalization, occurrence of megacolon, perfo-
ration or hemodynamic shock. Neither was the presence or
absence of pseudomembranes associated with prolongation of
the hospitalization, nor with higher rate of C. difficile
persistence or relapse (Table 1). Next, a multi-variate analysis
was performed to define whether parameters that correlated
with the presence of pseudomembranes in the uni-variate
analysis were independently associated with this endoscopic
finding. The results of the multi-variate analysis are shown in
Table 2 and show that fever remained associated with
appearance of pseudomembranes.4. Discussion
The present study examined the prevalence and clinical
correlates of pseudomembranes in IBD patients found to be
inflicted with CDAD.
Previous case-series anecdotally alluded to the rarity of
pseudomembranes in IBD population inflicted by C. difficile.
10,11 In one single-center study, no pseudomembranes were
detected in any of the 16 CDAD-IBD patients who underwent
lower endoscopy, although no details on the specific Endos-
copy performed (sigmoidoscopy or colonoscopy) were provid-
ed.12 The present study comprises the largest number of
endoscoped IBD patients with C. difficile to date, and
documents that endoscopic pseudomembranes are seldom
found in this population. It is known that in up to one third of
patients with CDAD, pseudomembranesmay be present only in
the right colon and may therefore be missed by a sigmoido-
scopic examination.7,13 Indeed, 7/37 (19%) of the patients who
underwent full colonoscopy had pseudomembranes compared
to only 5/56 (9%) of those who underwent only a sigmoido-
scopic examination; thereby suggesting the true incidence of
pseudomembranes in IBD patients may be somewhat higher.
However, this difference did not reach statistical significance,
and even the higher rate of 19% is still lower than the 50–60%
rate of endoscopically-visible pseudomembranes in reference
populations.14,15 It should be noted however, that not all
patients with CDAD in the general population have pseudo-
membranes, as some may have endoscopic non-specific
findings which correspond to grade 1 lesions on histology.16
Thus, caution should be employed when comparing pseudo-
membranes rate across populations. Nevertheless, as far as
endoscopically-visible lesions are concerned, the validity ofPlease cite this article as: Ben-Horin S, et al, Prevalence and cli
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procedures performed by large number of endoscopists from
different hospitals across Europe. This is likely to reduce the
probability of a false negative finding due to any individual
endoscopist awareness or judgment.
Why then are pseudomembranes rare in IBD patients with
C. difficile? One possibility is that the cases with pseudomem-
branes colitis are diluted by the high rate of C. difficile
asymptomatic carriage among IBD patients.9 As noted, it is also
possible that some patients have histo-pathological lesions of
lesser degree that are not detected by endoscopy.16 Yet
another explanation has been proposed by a recent study
reporting that concomitant immunosuppression prevents the
development of pseudomembranes.11 Whilst this is an attrac-
tive hypothesis, it was forwarded based on endoscopic findings
in only 4 IBD and 4 stem cell transplanted patients whowere all
taking immunomodulators. The present larger-scale study,
encompassing patients with and without concomitant immu-
nomodulators, could not corroborate that it is the concomitant
immunosuppression that predisposes to the absence of
pseudomembranes. Other background factors, such as a
younger age (IBD patients with CDAD may be younger than
the general population with CDAD) or prior exposure to
hospitalization and/or antibiotics were also not predictive of
the risk to develop pseudomembranes. The only factor
associated with the occurrence of pseudomembranes was
fever at presentation. This association, which may possibly be
present also in the general CDAD population, is intriguing as it
may suggest a more systemic inflammatory reaction in the
pseudomembranes cases. Conversely, it may otherwise point
to different dominant cytokine pathways in patients with or
without pseudomembranes. For instance, Il-6-dependent
pathways which also propagate fever could be hypothesized
to play a more dominant mechanistic role in patients with
pseudomembranes, although the similar elevations of CRP
among the two groups argue against this postulation. Thus,
more data is needed in order to elucidate this observed
correlation between fever at presentation and the develop-
ment of pseudomembranes and to investigate its pathogenic
implications.
The present study also addressed the question whether the
occurrence of pseudomembranes signifies a more severe
disease or an adverse outcome. This may be important
prognostic tool for early initiation of aggressive therapy for
high risk sub-groups. However, patients with pseudomem-
branes have not fared worst in clinical outcomes of death,
colectomy, relapse of CDAD, or the duration of hospitalization.
Several limitations of this study need to be acknowl-
edged. Fever was the only parameter differing between the
two groups, but the relative limited number of patients in
the pseudomembranes group (n=12) may possibly blunt
other dissimilarities. Another limitation is the fact that 4 out
of 12 patients with pseudomembranes came from a single
center, thereby possibly causing some skewing of the results.
However, taking out those patients from the analysis would
in fact strengthen the main finding of this study, namely,
that pseudomembranes are rare among IBD patients with
CDAD. Thus, this limitation probably does not affect the main
message of this work.
In conclusion, endoscopically-visible pseudomembranes are
seldom present in patients with CDAD-associated IBD exacer-
bation. The reason for this is unclear, but is not related tonical impact of endoscopic pseudomembranes in patients with
hn's Colitis (2009), doi:10.1016/j.crohns.2009.11.001
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The presence of pseudomembranes is associated with
fever on presentation, but is otherwise of little impact on the
clinical course or its outcome. Clinicians should be wary of
ruling out CDAD in IBD patients based on the absence of
pseudomembranes.
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